CALGB/SWOG 80405研究中结直肠癌患者的突变分析揭示微卫星不稳定性和肿瘤突变负荷对患者结局的新作用
CALGB/SWOG 80405是一项随机III期试验,在化疗联合贝伐珠单抗或西妥昔单抗一线治疗转移性结直肠癌中未发现总生存(OS)的统计学显著差异。对843例患者原发肿瘤DNA分析显示,高肿瘤突变负荷(TMB)患者OS较长(HR 0.73,95%CI 0.57-0.95,P=0.02)。微卫星高度不稳定(MSI-H)患者中贝伐珠单抗组OS优于西妥昔单抗组(HR 0.13,95%CI 0.06-0.30,交互P<0.001)。BRAF突变和扩展RAS突变均为不良预后因素。
要点
- 高TMB患者OS较长(HR 0.73,95%CI 0.57-0.95,P=0.02)。
- MSI-H患者中贝伐珠单抗组OS优于西妥昔单抗组(HR 0.13,95%CI 0.06-0.30,交互P<0.001)。
- BRAF突变和扩展RAS突变与较短OS相关(HR分别为2.01和1.52)。
核心结论
- 在一线治疗的转移性结直肠癌患者中,低TMB以及BRAF和RAS突变是不良预后因素。
- MSI-H肿瘤患者从贝伐珠单抗治疗中获益多于西妥昔单抗,需要研究来证实MSI-H的这一效应。
研究设计与样本
- CALGB/SWOG 80405是一项随机III期试验,比较化疗联合贝伐珠单抗或西妥昔单抗一线治疗转移性结直肠癌。
- 对843例患者原发肿瘤DNA进行基因检测以发现OS的遗传标志物。
- 基因突变通过聚合酶链反应确定,微卫星状态通过微卫星基因分型确定,TMB通过下一代测序确定。
- 使用Cox比例风险模型并校正因素,检验分子改变与贝伐珠单抗或西妥昔单抗组的交互作用。
主要发现
- 肿瘤高TMB患者OS长于低TMB患者(HR 0.73,95%CI 0.57-0.95,P=0.02)。
- MSI-H肿瘤患者中,贝伐珠单抗组OS长于西妥昔单抗组(HR 0.13,95%CI 0.06-0.30,微卫星状态与两组交互P<0.001)。
- BRAF突变肿瘤患者OS短于野生型患者(HR 2.01,95%CI 1.49-2.71,P<0.001)。
- 扩展RAS突变肿瘤患者OS短于野生型患者(HR 1.52,95%CI 1.26-1.84,P<0.001)。
- 三阴性肿瘤(NRAS/KRAS/BRAF均为野生型)患者中位OS为35.9个月(95%CI 33.0-38.8个月),而至少有一个基因突变的患者中位OS为22.2个月(95%CI 19.6-24.4个月)(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: CALGB/SWOG 80405 was a randomized phase III trial that found no statistically significant difference in overall survival (OS) in patients with first-line metastatic colorectal cancer treated with chemotherapy plus either bevacizumab or cetuximab. Primary tumor DNA from 843 patients has been used to discover genetic markers of OS. PATIENTS AND METHODS: Gene mutations were determined by polymerase chain reaction. Microsatellite status was determined by genotyping of microsatellites. Tumor mutational burden (TMB) was determined by next-generation sequencing. Cox proportional hazard models were used, with adjusting factors. Interaction of molecular alterations with either the bevacizumab or the cetuximab arms was tested. RESULTS: Patients with high TMB in their tumors had longer OS than did patients with low TMB (hazard ratio [HR], 0.73 [95% CI, 0.57 to 0.95]; P = .02). In patients with microsatellite instability-high (MSI-H) tumors, longer OS was observed in the bevacizumab arm than in the cetuximab arm (HR, 0.13 [95% CI, 0.06 to 0.30]; interaction P < .001 for interaction between microsatellite status and the two arms). Patients with BRAF mutant tumors had shorter OS than did patients with wild-type (WT) tumors (HR, 2.01 [95% CI, 1.49 to 2.71]; P < .001). Patients with extended RAS mutant tumors had shorter OS than did patients with WT tumors (HR, 1.52 [95% CI, 1.26 to 1.84]; P < .001). Patients with triple-negative tumors (WT for NRAS/KRAS/BRAF) had a median OS of 35.9 months (95% CI, 33.0 to 38.8 months) versus 22.2 months (95% CI, 19.6 to 24.4 months ) in patients with at least one mutated gene in their tumors (P < .001). CONCLUSION: In patients with metastatic colorectal cancer treated in first line, low TMB, and BRAF and RAS mutations are negative prognostic factors. Patients with MSI-H tumors benefited more from bevacizumab than from cetuximab, and studies to confirm this effect of MSI-H are warranted.
引用
- Innocenti F, Ou FS, Qu X, et al. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol. 2019. PMID: 30865548. doi:10.1200/JCO.18.01798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。